ENTRESTO®: The first and only treatment in its class (ARNI)2†

Angiotensin II and the natriuretic peptide (NP) system are two pathways involved in HFrEF1,8,9

Increased angiotensin
II activity

Prolonged angiotensin II
activity contributes to the
pathophysiology of HF

Increased neprilysin activity
(and reduced NP levels)

Expression and activation
of neprilysin are increased
in patients with HF, which
may contribute to
degradation of NPs

ENTRESTO®: Dual-component mechanism of action1‡

Valsartan

INHIBITS angiotensin II
through AT1 receptor
blockade


Vasodilation,
inhibition of renin/
aldosterone release

ENTRESTO®
(sacubitril + valsartan)

ARNI acts on both angiotensin II and the NP system via these two
mechanisms

Sacubitril

INCREASES levels of NPs
by inhibiting their degradation
by neprilysin


Vasodilation,
natriuresis, and
diuresis

Adapted from the ENTRESTO® Product Monograph.1

† Comparative clinical significance has not been established. ‡ Clinical significance has not been established. ARNI: angiotensin receptor-neprilysin inhibitor; AT1: angiotensin II Type-1; HF: heart failure; HFrEF: heart failure with reduced ejection fraction; NP: natriuretic peptide.